Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지

Radiation Therapy for Superior Vena Cava Syndrome

상대정맥증후군의 방사선치료

  • Kim, Jin-Hee (Department of Radiation Oncology, Keimyung University School of Medicine)
  • 김진희 (계명대학교 의과대학 방사선종양학교실)
  • Published : 2005.06.01
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The studied the effect of such variables as the symptom improvement rate, survival and prognostic factors on the treatment results of radiation therapy for Superior Vena Cava Syndrome (SVCS). Materials and Methods: From 1988 to 2003, seventy two patients with SVCS were treated with radiation therapy at the Department of Radiation Oncology, Keimyung University Dongsan Medical Center. The patients' ages ranged from 10 to 83 years old with the median age being 61, and sixty four patients were male. For the causes of the SVCS, 64 patients had lung cancer, four had metastatic lung cancer, two had malignant lymphoma and two had thymoma. The radiotherapy was delivered with 6-MV X-rays and all patients received above 900 cGy up to 6,600 cGy, with the median dose being 4,000 cGy The follow-up periods were from 1 to 180 months with a median of 5.6 months. Results: The main clinical manifestations were dyspnea ($84.7\%$), facial edema ($81.9\%$), arm edema ($22.2\%$), neck vein distension ($25\%$), hoarseness ($12.5\%$) and facial plethora ($5.6\%$). Eighty percent of patients achieved excellent to good symptom improvement and $19.4\%$ experienced minimal improvement. The median survival period was 5.1 months, and overall survival rates were $17.7\%$ at 2 years (2YOS) and $14.8\%$ at five years (5YOS) for all the patients. The median survival period, the two and five year disease free survival rates were 4.3 months, $16.7\%$ and $13.4\%$ for the lung cancer patients, respectively. The total tumor dose was a statistically significant survival factor on the univariate analysis for the patients with lung cancer (2YSR; > 30 Gy, $25.6\%$, $\leq$ 30 Gy $6.7\%$, p<0.01). On the multivariated analysis, a higher total tumor dose (p<0.01) and younger age (p<0.05) were statistically significant factors of survival for the lung cancer patients. Patients with NSCLC showed better survival than did the patients with SCLC, but this was not statistically significant (p > 0.05), Conclusion: Radiation therapy for the patients with SVCS due to malignancy could be an effective treatment. We considered that radiation therapy above 30 Gy of the total tumor dose may improve survival for SVCS due to lung cancer.

목적: 악성종양에 의한 상대정맥증후군에서 방사선치료 후의 증상완화율, 생존율, 예후인자를 알아보기 위해 연구를 시행 하였다. 대상 및 방법: 1988년부터 2003년까지 계명의대 동산의료원 방사선종양학과에서 상대정맥증후군으로 방사선치료를 받고 추적관찰이 가능했던 72명의 환자를 대상으로 하였다. 남자가 64명, 여자가 8명이었으며 연령은 10세에서 83세로 평균 61세였고 원인으로는 폐암 64명, 전이성 폐암 4명, 림프종 2명, 흉선종 2명이었다. 방사선 치료는 모든 환자를 900 cGy 이상 조사하였으며 총방사선량이 6,600 cGy까지 조사하여 중앙값은 4,000 cGy였다. 추적기간은 1개월에서 180개월로 중앙값 5.6개월이었다. 결과: 주증상은 호흡곤란 $84.7\%$, 안면부종 $81.9\%$, 팔부종 $22.2\%$, 경정맥확장 $25\%$, 애성 $12.5\%$, 안면홍조 $5.6\%$순이었다. 방사선치료 후 $80.6\%$에서 매우 우수(excellent)또는 우수(good)한 증상완화를 보였고 $19.4\%$에서는 변화가 없거나 경미한(minimal) 증상완화가 있었다. 전체 환자의 중앙생존기간은 5.1개월이었고 2년 생존율은 $17.7\%$, 5년 생존율은 $14.8\%$이었다. 폐암환자에서는 각각 4.3개월, $16.7\%$, $13.4\%$였다. 단변량분석에서 폐암환자는 총방사선량을 30 Gy초과로 조사 받은 군이 그 미만의 방사선을 조사 받은 군보다 통계적으로 유의하게 생존율의 차이를 보였다(2YSR; 30 Gy 초과 $25.6\%$, 30 Gy 이하 $6.7\%$, p<0.01). 다변량분석에서도 폐암에 의한 상대정맥증후군의 예후인자로는 총방사선량(p<0.01)과 연령(p<0.05)이 통계적으로 유의한 인자였다. 비소세포성폐암이 소세포성폐암보다 생존율이 높았으나 통계적으로 유의하지 않았다. 결과: 악성종양에 의한 상대정맥증후군에서 방사선치료는 효과적인 치료방법이며 폐암으로 인한 상대정맥증후군에서 총방사선량을 30 Gy 이상 조사하는 적극적인 치료로 생존율이 연장될 수 있으리라 생각된다.

Keywords

References

  1. Gauden SJ. Superior vena cava syndrome induced by bronchogenic carcinoma: is this an oncological emergency? Australas Radiol 1993;37:363-366 https://doi.org/10.1111/j.1440-1673.1993.tb00096.x
  2. Urban T, Lebeau B, Chastang C, et al. Superior vena cava syndrome in small-cell lung cancer. Arch Intern Med 1993;153:384-387 https://doi.org/10.1001/archinte.153.3.384
  3. Schechter MM. The superior vena cava syndome. Am J Med Sci 1954;227:46-56 https://doi.org/10.1097/00000441-195401000-00007
  4. Adar R, Rosenthal T, Mozes M. Vena Caval obstruction; some epidemiological observations in 76 patients. Angiology 1974;25:433-440 https://doi.org/10.1177/000331977402500701
  5. Bae JW, Oh S, Kang HJ, Kim KI, Park YB, Choi YS. A case of successful implantation of a DDD type permanent pacemaker in a patient with persistent left superior and absent right superior vena cava. Korean Circ J 2004;34:623-626 https://doi.org/10.4070/kcj.2004.34.6.623
  6. Yellin A, Rosen A, Reichert N, et al. Superior vena cava syndrome. The myth-the facts. Am Rev Respir Dis 1990;141:1114-1118 https://doi.org/10.1164/ajrccm/141.5_Pt_1.1114
  7. Gray BH, Olin JW, Graor RA, et al. Safety and efficacy of thrombolytic therapy for superior vena cava syndrome. Chest 1991;99:54-59 https://doi.org/10.1378/chest.99.1.54
  8. Goodwin RA, Nickell JA, Des Prez RM. Mediastinal fibrosis complicating healed primary histoplasmosis and tuberculosis. Medicine (Baltimore) 51 1972;51:227-246 https://doi.org/10.1097/00005792-197205000-00008
  9. Netter FH. Superior vena cava syndrome. In: Netter FH, ed. The CIBA Collection of Medical Illustrations: Respiratory System. Newark, NJ: CIBA Pharmaceutical Company. 1979:164
  10. Ahmann FR. A reassessment of the clinical implications of the superior vena caval syndrome. J Clin Oncol 1984;2:961-969 https://doi.org/10.1200/JCO.1984.2.8.961
  11. Abner A. Approach to the patient who presents with superior vena cava obstruction. Chest 1993;103(4 Suppl):S394-S397 https://doi.org/10.1378/chest.103.4_Supplement.394S
  12. Hsu JW, Chiang CD, Hsu WH, et al. Superior vena cava syndrome in lung cancer: an analysis of 54 cases. Gaoxiong Yi Xue Ke Xue Za Zhi 1995;11:568-573
  13. Chen JC, Bongard F, Klein SR. A contemporary perspective on superior vena cava syndrome. Am J Surg 1990;160:207-211 https://doi.org/10.1016/S0002-9610(05)80308-3
  14. Stanford W, Doty DB. The role of venography and surgery in the management of patients with superior vena cava obstruction. Ann Thorac Surg 1986;41:158-163 https://doi.org/10.1016/S0003-4975(10)62659-8
  15. Salsali M, Cliffton EE. Superior vena caval obstruction with lung cancer. Ann Thorac Surg 1968;6:437-442 https://doi.org/10.1016/S0003-4975(10)66050-X
  16. Schraufnagel DE, Hill R, Leech JA, et al. Superior vena caval obstruction. Is it a medical emergency? Am J Med 1981;70:1169-1174 https://doi.org/10.1016/0002-9343(81)90823-8
  17. Shimm DS, Logue GL, Rigsby LC. Evaluating the superior vena cava syndrome. JAMA 1981;245:951-953 https://doi.org/10.1001/jama.245.9.951
  18. Rosenbloom SE. Superior vena cava obstruction in primary cancer of the lung. Ann Intern Med 1949;31:470-478 https://doi.org/10.7326/0003-4819-31-3-470
  19. Armstrong BA, Perez CA, Simpson JR, et al. Role of irradiation in the management of superior vena cava syndrome. Int J Radiat Oncol Biol Phys 1987;13:531-539 https://doi.org/10.1016/0360-3016(87)90068-X
  20. Baker GL, Barnes HJ. Superior vena cava syndrome: etiology, diagnosis, and treatment. Am J Crit Care 192;1:54-64
  21. Gray BH, Olin JW, Graor RA, Young JR, Bartholomew JR, Ruschhaupt WF. Safety and efficacy of thrombolytic therapy for superior vena cava syndrome. Chest 1991;99:54-59 https://doi.org/10.1378/chest.99.1.54
  22. Tanigawa N, Sawada S, Mishima K, et al. Clinical outcome of stenting in superior vena cava syndrome associated with malignant tumors. Comparison with conventional treatment. Acta Radiol 1998;39:669-674 https://doi.org/10.3109/02841859809175494
  23. Nicholson AA, Ettles DF, Arnold A, et al. Treatment of malignant superior vena cava obstruction: metal stents or radiation therapy. J Vasc Interv Radiol 1997;8:781-788 https://doi.org/10.1016/S1051-0443(97)70660-2
  24. Dyet JF, Nicholson AA, Cook AM. The use of the Wallstent endovascular prosthesis in the treatment of malignant obstruction of the superior vena cava. Clin Radiol 1993;48:381-385 https://doi.org/10.1016/S0009-9260(05)81105-5
  25. Irving JD, Dondelinger RF, Reidy JF, et al. Gianturco self-expanding stents: clinical experience in the vena cava and large veins. Cardiovasc Intervent Radiol 1992;15:328-333 https://doi.org/10.1007/BF02733958
  26. Doty DB. Bypass of superior vena cava: Six years' experience with spiral vein graft for obstruction of superior vena cava due to benign and malignant disease. J Thorac Cardiovasc Surg 1982;83:326-338
  27. Kim YI, Kim KS, Ko YC, et al. Endovascular stenting as a first choice for the palliation of superior vena cava syndrome. J Korean Med Sci 2004;19:519-522 https://doi.org/10.3346/jkms.2004.19.4.519
  28. Rubin P, Ciccio S. High daily dose for rapid decompression. In: Deeley TJ, ed. Modern radiotherapy: Carcinoma of the broncus. New York: Appleton Century Crofts, 1971:276-297
  29. Chan RH, Dar AR, Yu E, et al. Superior vena cava obstruction in small-cell lung cancer. Int J Radiat Oncol Biol Phys 1997;38:513-520 https://doi.org/10.1016/S0360-3016(97)00094-1
  30. Worschmidt F, Bunemann H, Heilmann HP. Small cell lung cancer with and without superior vena cava syndrome: a multivariate analysis of prognostic factors in 408 cases. Int J Radiat Oncol Biol Phys 1995;33:77-82 https://doi.org/10.1016/0360-3016(95)00094-F
  31. Rodrigues CI, Njo KH, Karim AB. Hypofractionated radiation therapy in the treatment of superior vena cava syndrome. Lung Cancer 1993;10:221-228 https://doi.org/10.1016/0169-5002(93)90182-W
  32. Maddox AM, Valdivieso M, Lukeman J, et al. Superior vena cava syndrome in small cell lung carcinoma. Cancer 1983;52:2165-2172 https://doi.org/10.1002/1097-0142(19831201)52:11<2165::AID-CNCR2820521132>3.0.CO;2-Z